Socioeconomic Inequalities and Type 2 Diabetes Comorbidities: A Systematic Review and Meta‐Analysis on Observational Studies
Endocrinology, Diabetes & Metabolism · 2026
DOI: 10.1002/edm2.70160 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2026. Verfasst von Mansour Bahardoust und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, School of Public Health & Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Social Class, Health Status Disparities. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Previous studies have reported inconsistent findings regarding the relationship between socioeconomic status (SES) inequalities and comorbidities in patients with diabetes mellitus (DM). This systematic review and meta‐analysis aims to evaluate, for the first time, the association between SES inequalities and comorbidities in individuals with DM.
Methods
Two independent investigators searched the PubMed, Embase, Scopus, Web of Science and Google Scholar databases using MeSH terms to identify studies that investigated the association between SES and DM comorbidities up to 15 December 2025. This systematic review followed the PRISMA 2020 checklist. Heterogeneity among studies was assessed using Cochran's Q and I 2 statistics. Meta‐regression was used to control for heterogeneity; Egger's test assessed publication bias.
Results
Thirteen studies involving 757,599 DM patients were included. A pooled estimate of 13 studies showed that low SES, compared with moderate or high SES, was significantly associated with an increased probability of DM comorbidities (OR: 1.43; 95% CI: 1.30, 1.59; I 2 : 92.7, p : 0.01). Subgroup analysis of 12 studies showed that the probability of DM comorbidities was different in men (OR: 1.30; 95% CI: 1.28, 1.32) and women (OR: 1.39; 95% CI: 1.36, 1.42).
Conclusion
The chance of developing type 2 diabetes comorbidities in patients with T2DM of low SES, especially in women, may be higher than in patients with middle and high SES. Improvements in healthcare systems and interventions to reduce inequalities in SES in patients with type 2 diabetes, especially in patients with low SES, are recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology, School of Public Health & Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Mass General Hospital Institute of Health Professions, Boston, Massachusetts, USA.
- Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Child and Adolescent Mental Health Center, Mental Health Services, Capital Region of Denmark, Copenhagen, Denmark.
- Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Mansour Bahardoust, Sheida Shokohyar
Zitieren
APA
Bahardoust, M., Shokohyar, S., Maleki, F., Shafiee, A., Tehrani, F. M., & Ghaffari, A. (2026). Socioeconomic Inequalities and Type 2 Diabetes Comorbidities: A Systematic Review and Meta‐Analysis on Observational Studies. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70160
Vancouver
Bahardoust M, Shokohyar S, Maleki F, Shafiee A, Tehrani FM, Ghaffari A. Socioeconomic Inequalities and Type 2 Diabetes Comorbidities: A Systematic Review and Meta‐Analysis on Observational Studies. Endocrinology, Diabetes & Metabolism. 2026. doi:10.1002/edm2.70160
BibTeX
@article{Bahardoust2026,
author = {Bahardoust, Mansour and Shokohyar, Sheida and Maleki, Farzad and Shafiee, Atefe and Tehrani, Farshid Monshizadeh and Ghaffari, Azin},
title = {Socioeconomic Inequalities and Type 2 Diabetes Comorbidities: A Systematic Review and Meta‐Analysis on Observational Studies},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
doi = {10.1002/edm2.70160}
}
EUVIMED